<DOC>
	<DOCNO>NCT00394966</DOCNO>
	<brief_summary>This Phase 2 , randomize , multicenter , parallel-group , double-blind , placebo-controlled study various dos SCH 619734 subject receive cisplatin-based chemotherapy . Ondansetron dexamethasone concurrently administer SCH 619734 initiation chemotherapy Day 1 . Subjects record nausea vomit SPNV Subject Diary Day 6 . The quality life assessment measure Functional Living Index-Emesis Questionnaire ( FLIE ) use measure effect chemotherapy-induced nausea vomiting ( CINV ) daily life . Blood sample SCH 619734 pharmacokinetic assessment collect . The study conduct conformance Good Clinical Practice .</brief_summary>
	<brief_title>A Multicenter , Randomized , Controlled Trial SCH 619734 Treatment Chemotherapy-Induced Nausea Vomiting ( Study P04351AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<criteria>Subject 18 year age old . Subject never treat cisplatin receive first course cisplatinbased chemotherapy ( &gt; =70 mg/m^2 ) . Subject Karnofsky performance score &gt; =60 . Subject predict life expectancy &gt; =3 month . Subject adequate bone marrow , kidney , liver function evidence : Absolute neutrophil count &gt; =1,500/mm3 white blood cell count &gt; =3,000/mm3 . Platelet count &gt; =100,000/mm3 . Aspartate aminotransferase ( AST ) &lt; =2.5 x upper limit normal ( ULN ) range . Alanine aminotransferase ( ALT ) &lt; =2.5 x ULN . Bilirubin &lt; =1.5 x ULN , except subject Gilbert 's syndrome . Creatinine &lt; =1.5 x ULN . Subject able read , understand , complete questionnaire . Any current treatment medical history ( eg , subject mentally incapacitated psychiatric disorder ) , opinion investigator , would confound result study pose unwarranted risk administer study drug subject . Subject contraindication administration cisplatin , ondansetron , dexamethasone include , limited , history hypersensitivity drug component , severe renal impairment , severe bone marrow suppression , hear impairment , systemic fungal infection . Subject schedule receive chemotherapeutic agent emetogenicity level 3 ( Hesketh Scale ) Day 2 Day 6 . Subject schedule receive radiation therapy abdomen pelvis within 5 day prior and/or Days 1 5 follow cisplatin infusion . Subject symptomatic primary metastatic central nervous system ( CNS ) disease . Subject ongoing vomiting cause etiology history anticipatory nausea vomiting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>